Michael H. Kagey
0000-0002-5536-0877
Publication & Citation Trends
Publications
0 total
Author Correction: DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B
Cited by 0
Semantic Scholar
DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B
Cited by 4
Semantic Scholar
DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish
Cited by 21
Semantic Scholar
Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumab OA
Cited by 2
Semantic Scholar
A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC) OA
Cited by 7
Semantic Scholar
A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab + chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA).
Cited by 10
Semantic Scholar
DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
Cited by 18
Semantic Scholar
553 DKN-01 and tislelizumab as a second-line (2L) investigational therapy in advanced DKK1 high gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial OA
Cited by 1
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(20)
Immune Cell Function and Interaction
(15)
Cancer-related gene regulation
(14)
Gastric Cancer Management and Outcomes
(12)
Wnt/β-catenin signaling in development and cancer
(10)
Affiliations
Bucknell University
Q Therapeutics (United States)
Learning Through an Expanded Arts Program
Sage Therapeutics (United States)
Ensemble Therapeutics (United States)